Post job

Second Genome's revenue is $12.0 million.

What is Second Genome's revenue?

Second Genome's annual revenue is $12.0M. Zippia's data science team found the following key financial metrics about Second Genome after extensive research and analysis.
  • Second Genome has 60 employees, and the revenue per employee ratio is $200,000.
  • Second Genome peak revenue was $12.0M in 2024.

On this page

Peak revenue
$12.0M (2024)
Company peak revenue
Revenue / employee
$200,000
Company revenue / employee

Zippi applies for you, and finds you a job.

Floating question marks illustration
Peak revenue
$12.0M (2024)
Company peak revenue
Revenue / employee
$200,000
Company revenue / employee

Second Genome financing

Second Genome received early financing of $5.0M on 2011-08-09.

SeriesRound sizeDate
Series A$5.0M08/2011
Series A$6.5M06/2013
Series B$51M04/2016

Second Genome investors

InvestorsSecurity type
ADVANCED TECHNOLOGY VENTURESSeries A
Morgenthaler VenturesSeries A
Wavepoint VenturesSeries A
SR OneSeries B
MBL Venture Capital Co LtdSeries B
Pfizer Venture InvestmentsSeries B
AdveqSeries B
Roche Venture FundSeries B
Mayo ClinicSeries B
ADVANCED TECHNOLOGY VENTURESSeries B
Morgenthaler VenturesSeries B
Lifeforce CapitalSeries B
Digitalis VenturesSeries B
Matt WinklerSeries B
Seraph GroupSeries B

Second Genome competitors

Second Genome's top competitor, Vertex Pharmaceuticals, earned an annual revenue of $11.0B.

Second Genome's smallest competitor is Phosphorus with revenue of $1.0M last year.

Second Genome revenue FAQs

Search for jobs

Zippia gives an in-depth look into the details of Second Genome, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Second Genome. The employee data is based on information from people who have self-reported their past or current employments at Second Genome. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Second Genome. The data presented on this page does not represent the view of Second Genome and its employees or that of Zippia.

Second Genome may also be known as or be related to Second Genome, Second Genome Inc, Second Genome Inc. and Second Genome, Inc.